10/520925

DT15 Rec'd PCT/PTO 70 7 JAN 2005

DATE OF DEPOSIT 2/12

EXPRESS MAIL NO. 1 HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL POST OFFICE TO ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINA 22813-1450.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE AS DESIGNATED/ELECTED OFFICE

Applicants:

D. Olsen, et al.

Int. Appln. No:

PCT/US03/22556

Int. Filing Date:

18 July 2003

US Appln. No.:

To Be Assigned

Case No.: 21194P

Art Unit:

Filed:

Concurrently Herewith

Examiner:

For:

THIONUCLEOSIDE DERIVATIVES AS

INHIBITORS OF RNA-DEPENDENT RNA VIRAL

POLYMERASE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Sir:

The above-identified case is a PCT application entering the US National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty. Applicants respectfully request entry of the following amendments prior to prosecution of the subject application. Any additional fees associated with this Amendment may be charged to Merck Deposit Account No. 13-2755.

Amendments to the Specification are reflected on page 2 of this response.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this response.

Remarks begin on page 7 of this response.